•
RO
ROIV
Roivant Sciences Ltd. Common Shares
polygonPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
15.98B
Volume
615.73K
52W High
$23.91
52W Low
$8.73
Open
$23.02
Prev Close
$22.98
Day Range
22.68 - 23.05
About Roivant Sciences Ltd. Common Shares
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Latest News
Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report
Benzinga•Jan 20
Is Immunovant Stock a Buy After Roivant Sciences Increased Its Stake by $350 Million?
The Motley Fool•Dec 18
Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)
GlobeNewswire Inc.•Sep 17
Imbria Pharmaceuticals Strengthens Leadership with New Board and Key Clinical Appointments
GlobeNewswire Inc.•Sep 16
Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
GlobeNewswire Inc.•Sep 4
Immunovant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
GlobeNewswire Inc.•Sep 3
Will Moderna Stock Drop to $25? 1 Wall Street Analyst Thinks So.
The Motley Fool•Feb 20
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
Benzinga•Oct 28